Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson is a More Attractive Stock Than its Rivals

By Bob Ciura - Jan 16, 2014 at 5:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Johnson & Johnson is much cheaper than Bristol-Myers Squibb, and is performing better than Merck. That's what makes it the most attractive large-cap health care stock your money can buy.

As the markets keep ripping higher, you might be reluctant to commit new capital. After all, the stock market closed 2013 at record levels. In fact, the S&P 500 just wrapped up its best year in the last 16, and the Dow booked its best annual performance in 18 years. As a result, you'd think the search for modestly priced blue chips would be difficult.

At first glance, health care giant Johnson & Johnson (JNJ 0.89%) looks fairly expensive. But the truth is, J&J's earnings were unfairly punished over the past year, and in addition, its rivals are even more aggressively valued. Those investors not giving J&J its due could be missing out on an opportunity.

Some health care stocks look downright expensive

On most investing web sites, J&J appears to have a price to earnings ratio of over 20 times. This looks expensive, but that level still compares very well to the valuation of Bristol-Myers Squibb (BMY 1.17%) Bristol-Myers Squibb expects to earn $1.74 in adjusted earnings this year, which would place its 2013 P/E at approximately 30 times. Bristol-Myers Squibb is doing a nice job of growing its business, as its core earnings rose 12% in the most recent quarter. But it holds a valuation multiple that should make you pause.

Plus, a deeper analysis of J&J reveals it's even cheaper than it seems. J&J's earnings were depressed for most of 2013 due to one-time charges and other non-recurring items. Consider that J&J expects to earn at least $5.44 per share in adjusted profits in 2013, which exclude the impact of special items. Such items include litigation expenses, in-process research and development, and intangible asset write downs, all of which have hidden J&J's true earnings potential.

In all, these one-time items have depressed J&J's profits by more than $2.5 billion through the first three quarters. Assuming J&J hits its goal when it reports full-year results on January 21, its trailing P/E multiple will actually be 17.4 times.

In fact, J&J's core operating earnings make the stock look cheap not just in comparison to the overall market, but when evaluated against some of its peers. Some big pharma stocks are even more aggressively valued by the market.

Why operational excellence separates Johnson & Johnson
Admittedly, J&J isn't the cheapest pharmaceutical stock. Some of its rivals are indeed cheaper, but for good reason. For example, pharmaceutical giant Merck (MRK 1.03%) advises investors it should earn $3.50 in non-GAAP adjusted earnings, at the midpoint of its guidance. While Merck is cheaper than J&J on a trailing basis, (the stock changes hands for 14 times 2013 earnings), an important caveat needs to be considered.

J&J has a distinct advantage over Merck, in that their respective profits are going in opposite directions. Merck's full-year earnings guidance represents a decline versus the prior fiscal year. Merck has warned that its 2013 net income will decrease by as much as $5.6 billion versus 2012. Revenue is expected to fall between 5% to 6%. This is because Merck continues to struggle with patent expirations.

By contrast, J&J's world-class businesses make it a truly one-of-a-kind company. J&J has grown its adjusted earnings for 29 years in a row, and will likely make it 30 when the company reports its 2013 full-year earnings. Results through the first nine months of 2013 were very encouraging. Excluding the impacts of currency fluctuations, J&J grew sales in all three core operating segments (consumer, pharmaceutical, and medical devices) in the third quarter.

Pass on J&J at your own risk
J&J is much more attractive than it seems on the surface, as it's been punished for one-time charges against earnings. The truth is that J&J is actually cheaper than both the market and major competitor Bristol-Myers Squibb. And, J&J is in a better position than Merck. As a result, J&J is much cheaper than it seems, and is still a value stock at today's price.

Bob Ciura has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.34 (1.03%) $0.94
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$168.26 (0.89%) $1.49
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.02 (1.17%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.